Fosfomycin does cover Proteus mirabilis in laboratory testing, with susceptibility rates around 92% in clinical isolates from urinary tract infections. However, the real-world picture is more nuanced than that number suggests, especially when it comes to different types of infections and drug-resistant strains.
What Lab Testing Shows
In a large study using agar dilution methods on clinical UTI isolates, 92.3% of Proteus mirabilis samples were susceptible to fosfomycin. That’s a strong number, though notably lower than E. coli, which typically tests susceptible at rates above 95%. Fosfomycin is formally listed on the FDA label as having activity against Proteus mirabilis in lab settings, with most strains showing low minimum inhibitory concentrations. The FDA label does include an important caveat: while fosfomycin inhibits Proteus mirabilis in the lab, its clinical effectiveness against this organism specifically has not been established in controlled trials.
The susceptibility picture changes significantly when drug-resistant bacteria are involved. Among ESBL-producing Enterobacteriaceae (bacteria that have developed resistance to many common antibiotics), fosfomycin susceptibility for Proteus species drops to 50 to 72%. That’s a meaningful decline from the 92% seen in general clinical isolates, and it matters because Proteus infections are increasingly showing up in patients who have already been through rounds of other antibiotics.
How Fosfomycin Works Against Proteus
Fosfomycin kills bacteria by blocking the very first step in building the cell wall. It mimics a natural molecule the bacteria need for this process and permanently binds to the enzyme responsible, shutting down cell wall production. Without a functioning cell wall, the bacteria can’t survive. This mechanism works broadly across gram-negative organisms, including Proteus mirabilis.
Proteus mirabilis can develop resistance to fosfomycin, primarily through mutations that disable the transport channels bacteria use to bring the drug inside their cells. If fosfomycin can’t get into the bacterial cell, it can’t reach its target. Other resistance pathways include changes to the target enzyme itself and, less commonly, the acquisition of genes that produce enzymes capable of breaking down the drug. One concern specific to Proteus mirabilis is that some clinical isolates show an increased tendency to develop these resistance mutations compared to other bacteria.
Uncomplicated vs. Complicated UTIs
For uncomplicated UTIs (simple bladder infections in otherwise healthy women), a single oral dose of fosfomycin is one of the recommended first-line treatments. This indication is well established for E. coli, which causes the majority of these infections. When Proteus mirabilis is the culprit in an uncomplicated UTI, fosfomycin is a reasonable option based on the high in vitro susceptibility rates, though the clinical evidence base is thinner than it is for E. coli.
Complicated UTIs are a different story. These involve factors like urinary tract abnormalities, catheters, kidney involvement, or infections in patients with other health conditions. Proteus mirabilis plays a larger role in complicated UTIs than in simple ones, making this distinction particularly relevant. Clinical experience with fosfomycin for complicated Proteus infections is growing but still limited. One outpatient study using multiple doses of fosfomycin for complicated UTIs found clinical resolution in only 1 out of 4 patients with Proteus species infections, compared to 75% for E. coli. The sample size was tiny, so it’s hard to draw firm conclusions, but the numbers are not encouraging. No randomized controlled trials have evaluated fosfomycin specifically for complicated UTIs caused by Proteus.
How Fosfomycin Compares to Nitrofurantoin
This comparison matters because both fosfomycin and nitrofurantoin are commonly used oral antibiotics for UTIs, but they behave very differently against Proteus mirabilis. Nitrofurantoin has notoriously poor activity against Proteus species. In one study, 100% of Proteus isolates were resistant to nitrofurantoin, while 0% were resistant to fosfomycin. This is a well-known pattern: Proteus mirabilis is intrinsically resistant to nitrofurantoin, making it essentially useless against this organism.
So if you have a UTI caused by Proteus mirabilis and need an oral antibiotic, fosfomycin has a clear advantage over nitrofurantoin. Overall susceptibility testing in one study showed uropathogens were susceptible to fosfomycin at 99.3% compared to 81.2% for nitrofurantoin, though these numbers reflect all organisms combined, not Proteus specifically.
Testing and Breakpoint Challenges
One complication with fosfomycin and Proteus mirabilis is the way susceptibility testing works. The established European breakpoint for oral fosfomycin classifies bacteria as susceptible at concentrations of 8 mg/L or below. However, these breakpoints were originally developed based on E. coli data. For non-E. coli organisms like Proteus mirabilis, the same cutoffs are applied in the absence of species-specific criteria, which introduces some uncertainty into susceptibility results.
Some automated testing systems used in hospital labs can’t even detect susceptibility at the 8 mg/L threshold, which means labs sometimes use a higher cutoff and may overestimate how many isolates are truly susceptible. If your culture report shows Proteus mirabilis as susceptible to fosfomycin, the result is still informative, but these testing limitations are worth knowing about.
The Bottom Line on Coverage
Fosfomycin covers Proteus mirabilis on paper, with over 90% of general clinical isolates testing susceptible. It’s a genuinely useful option for uncomplicated UTIs caused by this organism, particularly since one of the other go-to oral antibiotics, nitrofurantoin, doesn’t work against Proteus at all. The picture is less clear for complicated infections, drug-resistant strains, and clinical cure rates, where the data either shows lower susceptibility or is simply too limited to be confident. Culture and susceptibility results from your specific infection are the most reliable guide when Proteus mirabilis is identified as the cause.